(21 days)
The Autosuture™ Endo GIA™ Staplers with Endo GIA™ Single Use Reloads have applications in abdominal, gynecologic, pediatric and thoracic surgery for resection. transection and creation of anastomosis. They may be used for transection and resection of liver substance, hepatic vasculature and biliary structures.
The Endo GIA™ Single Use Tan Reload with Tri-Staple™ Technology when used with the Endo GIA™ Stapler places two, triple-staggered rows of titanium staples and simultaneously divides the tissue between the two, triple-staggered rows. For the Tan reload, the staple sizes are 2.0, 2.5, and 3.0 mm for use in vascular and medium thick tissue. The Tan Reloads are available in 30mm. 45mm and 60mm staple line lengths as well as curved-tip anvil configurations. Tri-Staple™ Technology means that each of the two triple-staggered rows has a stepped configuration whereby the staples in the outer row are a taller height than the staples in the middle row which in turn are a taller height than the staples in the inner row. The size of the staples is determined by the selection of the appropriate single use Reload.
The provided text describes a 510(k) premarket notification for a surgical stapler reload. The focus of this submission is a change in the upper range of the tissue thickness compression contraindication from 1.5 mm to 1.8 mm for the Autosuture™ Endo GIA™ Single Use Tan Reload with Tri-Staple™ Technology.
Here's an analysis of the acceptance criteria and the study that proves the device meets them, based only on the provided text:
Key Takeaways from the Document:
- Device: Autosuture™ Endo GIA™ Single Use Tan Reload with Tri-Staple™ Technology (used with the Autosuture™ Endo GIA™ Stapler).
- Change: Modified contraindication for tissue thickness, increasing the upper limit from 1.5 mm to 1.8 mm.
- Purpose of Study: To demonstrate that the device is safe and effective and performs as intended with the new tissue thickness range.
- Tests Conducted: Bench tests (staple formation) and in vivo tests (staple formation, hemostasis, burst strength).
- Regulatory Context: This is a 510(k) submission, meaning the device is seeking substantial equivalence to a legally marketed predicate device. The change is a labeling modification.
1. Table of Acceptance Criteria and Reported Device Performance
Based solely on the provided text, the acceptance criteria are implicitly related to the performance characteristics evaluated in the study. The actual numerical acceptance criteria (e.g., minimum burst strength, specific hemostasis metrics) are not detailed in this summary.
| Acceptance Criteria (Implied) | Reported Device Performance (Summary) |
|---|---|
| Bench Tests: | |
| Proper Staple Formation within the revised tissue thickness range | Bench tests were performed to evaluate staple formation, demonstrating safe and effective performance. |
| In Vivo Tests: | |
| Proper Staple Formation within the revised tissue thickness range | In vivo tests were performed to evaluate staple formation, demonstrating safe and effective performance. |
| Adequate Hemostasis within the revised tissue thickness range | In vivo tests were performed to evaluate hemostasis, demonstrating safe and effective performance. |
| Adequate Burst Strength within the revised tissue thickness range | In vivo tests were performed to evaluate burst strength, demonstrating safe and effective performance. |
| Biocompatibility | All components are comprised of materials in accordance with ISO Standard 10993-1. |
| Overall Safety and Effectiveness | Bench and in vivo performance evaluations were conducted to demonstrate that the device is safe and effective and performs as intended. |
Important Note: The document states that these tests were conducted to demonstrate safety and effectiveness and "performed as intended," implying the acceptance criteria were met. However, the specific quantitative criteria (e.g., "burst strength must exceed X psi") are not explicitly stated in this high-level summary.
2. Sample Size Used for the Test Set and the Data Provenance
- Sample Size for Test Set: Not specified. The document mentions "bench tests" and "in vivo tests" but does not provide the number of samples, animals, or tests conducted.
- Data Provenance:
- Country of origin: Not specified.
- Retrospective or prospective: The tests ("bench tests were performed," "in vivo tests were performed") suggest a prospective study design, as they were conducted to support the labeling modification.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and the Qualifications of Those Experts
- Not Applicable. This device is a surgical stapler reload. "Ground truth" in the context of expert review for diagnostic imaging or similar AI applications is not relevant here. The performance is assessed through objective physical and biological tests (staple formation, hemostasis, burst strength). The analysis of these tests would be conducted by qualified engineers and scientists, but the concept of "ground truth" established by a panel of medical experts is not directly applicable to a mechanical device performance study.
4. Adjudication Method for the Test Set
- Not Applicable. As explained above, for a mechanical device performance study, an adjudication method for test set ground truth is not typically used. The data from the bench and in vivo tests would be analyzed according to predefined protocols and statistical methods.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- No. This is not an AI-assisted diagnostic device. Therefore, an MRMC study is not relevant.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- Not Applicable. This is a mechanical surgical device, not an algorithm.
7. The Type of Ground Truth Used
- The concept of "ground truth" as a reference standard for diagnostic accuracy (e.g., pathology, expert consensus) is not directly applicable here.
- Instead, the "ground truth" or reference for evaluating performance would be derived from:
- Engineering specifications and standards: For staple formation (geometric precision, integrity).
- Physiological measurements: For hemostasis (e.g., absence of bleeding, blood loss quantification).
- Biomechanical testing standards: For burst strength (e.g., pressure at which the staple line fails).
- ISO Standard 10993-1: For biocompatibility.
8. The Sample Size for the Training Set
- Not Applicable. This is a mechanical device, not a machine learning model. Therefore, there is no "training set." The device design and manufacturing processes are developed through engineering principles, prototyping, and testing, not by training an algorithm on a dataset.
9. How the Ground Truth for the Training Set Was Established
- Not Applicable. As there is no "training set" for a mechanical device, there is no ground truth to establish for it.
{0}------------------------------------------------
510(k) Summary of Safety and Effectiveness
| SUBMITTER: | Surgical Devices, a global business unitof Tyco Healthcare Group LP (d/b/a Covidien)60 Middletown AvenueNorth Haven, CT 06473Tel. No.: (203) 492-5352 |
|---|---|
| ------------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
JUN 1 4 2010
CONTACT PERSON: Frank Gianelli Senior Associate, Regulatory Affairs
May 21, 2010 DATE PREPARED:
TRADE/PROPRIETARY NAME: Autosuture™ Endo GIA™ Staplers
COMMON/USUAL NAME: Surgical Stapler with Implantable Staples
CLASSIFICATION NAME: Staples, Implantable
Autosuture™ Endo GIA™ Stapler (K083519) PREDICATE DEVICE(S):
The Endo GIA™ Single Use Tan Reload with Tri-Staple™ Technology when used with the Endo GIA™ Stapler places two, triple-staggered rows of titanium staples and simultaneously divides the tissue between the two, triple-staggered rows.
For the Tan reload, the staple sizes are 2.0, 2.5, and 3.0 mm for use in vascular and medium thick tissue. The Tan Reloads are available in 30mm. 45mm and 60mm staple line lengths as well as curved-tip anvil configurations.
The Autosuture™ Endo GIA™ Staplers have applications in abdominal, gynecologic, pediatric and thoracic surgery for resection, transection, and creation of anastomoses. They may be used for transection and resection of liver substance, hepatic vasculature and biliary structures.
Note: The Endo GIA™ Single Use Tan Reload with Tri-Staple™ Technology is intended for use with the Autosuture™ Endo GIA™ Stapler and does not carry a separate indication from the stapling device.
This 510(k) reports for the previously cleared Endo GIA™ Single Use Tan Reload with Tri-Staple™ Technology a change in the upper range of the tissue thickness compression contraindication from 1.5 mm to 1.8 mm. Except for this labeling change, there are no other changes to the currently marketed device as well as no change to indications for use, or to the intended use of the device.
Tri-Staple™ Technology means that each of the two triplestaggered rows has a stepped configuration whereby the staples in the outer row are a taller height than the staples in the middle row which in turn are a taller height than the staples in the inner row. The size of the staples is determined by the selection of the appropriate single use Reload.
INTENDED USE:
DEVICE DESCRIPTION:
TECHNOLOGICAL CHARACTERISTICS:
{1}------------------------------------------------
MATERIALS:
PERFORMANCE DATA:
All components of the Endo GIA™ Single Use Tan Reload with Tri-Staple™ Technology are comprised of materials that are in accordance with ISO Standard 10993-1.
Bench and in vivo performance evaluations were conducted to demonstrate that the Endo GIA™ Single Use Tan Reload with Tri-Staple™ Technology when used with the Autosuture™ Endo GIA™ Stapler is safe and effective and performs as intended.
In support of this product labeling modification, bench tests were performed to evaluate staple formation and in vivo tests were performed to evaluate staple formation, hemostasis and burst strength.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo consists of a stylized eagle with three tail feathers, representing the three levels of government: federal, state, and local. The eagle is surrounded by a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" written around it.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Surgical Devices, a global business unit Of Tyco Healthcare Group LP % Covidien Mr. Frank Gianelli Senior Associate, Regulatory Affairs 60 Middletown Avenue North Haven, Connecticut 06473
JUN 1 4 2010
Re: K101444
Trade/Device Name: Autosuture™ Endo GIA™ Single Use Tan Reload with Tri-Staple" Technology Regulation Number: 21 CFR 878.4750 Regulation Name: Implantable staple Regulatory Class: Class II Product Code: GDW Dated: May 21, 2010 Received: May 24, 2010
Dear Mr. Gianelli:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{3}------------------------------------------------
Page 2 - Mr. Frank Gianelli
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance,
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Mark A Millman
Mark N. Melkerson Director Division of Surgical, Orthopedic And Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Indications for Use
510(k) Number (if known): K101444
Device Name: Autosuture™ Endo GIA™ Single Use Tan Reload with Tri-Staple™ Technology
The Autosuture™ Endo GIA™ Staplers with Endo GIA™ Single Use Reloads have applications in abdominal, gynecologic, pediatric and thoracic surgery for resection. transection and creation of anastomosis. They may be used for transection and resection of liver substance, hepatic vasculature and biliary structures.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Daniel Kronebaumxm
Division of Surgical, Orthopedic. and Restorative Devices
Page 1 of
510(k) Number K101444
§ 878.4750 Implantable staple.
(a)
Identification. An implantable staple is a staple-like device intended to connect internal tissues to aid healing. It is not absorbable.(b)
Classification. Class II.